T. Rowe Price Investment Management Inc. Has $167.83 Million Holdings in Elanco Animal Health Incorporated $ELAN

Key Points

• T. Rowe Price Investment Management Inc. has increased its stake in Elanco Animal Health by 1.9%, owning approximately 15,983,391 shares valued at $167,826,000.
• Research analysts are optimistic about Elanco, with multiple upgrades from various firms, increasing price targets to as high as $18.00 and assigning a consensus rating of "Moderate Buy."
• Elanco reported a 4.8% increase in revenue year-over-year, with EPS surpassing analysts' expectations, highlighting a strong Q2 performance.

T. Rowe Price Investment Management Inc. grew its stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 1.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,983,391 shares of the company's stock after acquiring an additional 292,655 shares during the period. T. Rowe Price Investment Management Inc. owned 3.22% of Elanco Animal Health worth $167,826,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of ELAN. Raymond James Financial Inc. boosted its position in Elanco Animal Health by 9.1% during the first quarter. Raymond James Financial Inc. now owns 951,791 shares of the company's stock valued at $9,994,000 after purchasing an additional 79,668 shares during the last quarter. Sector Gamma AS raised its stake in shares of Elanco Animal Health by 72.3% during the 1st quarter. Sector Gamma AS now owns 477,073 shares of the company's stock worth $5,009,000 after purchasing an additional 200,166 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Elanco Animal Health by 14.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company's stock valued at $214,875,000 after buying an additional 2,563,740 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Elanco Animal Health by 695.7% in the 1st quarter. Russell Investments Group Ltd. now owns 201,389 shares of the company's stock valued at $2,115,000 after buying an additional 176,078 shares during the last quarter. Finally, Callan Family Office LLC grew its stake in shares of Elanco Animal Health by 33.5% in the first quarter. Callan Family Office LLC now owns 49,024 shares of the company's stock valued at $515,000 after buying an additional 12,304 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Piper Sandler increased their price target on shares of Elanco Animal Health from $12.00 to $18.00 and gave the company a "neutral" rating in a research note on Monday, August 11th. William Blair raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a report on Thursday, June 26th. Leerink Partners upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 target price for the company in a research note on Thursday, July 17th. Stifel Nicolaus boosted their price target on Elanco Animal Health from $16.00 to $17.00 and gave the stock a "buy" rating in a research report on Wednesday, July 2nd. Finally, Leerink Partnrs upgraded Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $17.33.

Elanco Animal Health Stock Performance

Shares of NYSE:ELAN traded up $0.17 during trading on Tuesday, reaching $17.96. 744,374 shares of the stock were exchanged, compared to its average volume of 5,430,734. Elanco Animal Health Incorporated has a 12 month low of $8.02 and a 12 month high of $18.08. The stock has a 50-day moving average price of $15.16 and a 200-day moving average price of $12.52. The company has a current ratio of 2.60, a quick ratio of 1.40 and a debt-to-equity ratio of 0.61. The firm has a market cap of $8.92 billion, a PE ratio of 20.88, a PEG ratio of 3.32 and a beta of 1.66.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.06. The business had revenue of $1.24 billion during the quarter, compared to analysts' expectations of $1.19 billion. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The firm's revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period last year, the firm posted $0.30 EPS. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Research analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.